EICHOR
● Recruiting
ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies
Condition: Advanced EGFR Positive Solid Tumor · Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD
About this study
This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Malignancies who are not able to have current standard anti-tumor therapies. The purpose of this study is to determine the maximum tolerated dose (MTD) , to characterise the safety, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of ZZ06 as a single agent in adult participants with advanced solid tumors.
This description comes directly from the study's public registry record.
Talk to the study team
Shiqi Bai · 18943642700 · baishiqi@intelli-crown.com
Always discuss trial participation with your own doctor first.
Locations (5)
| Cedars Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Kansas University Cancer Center | Fairway, Kansas, United States | Recruiting |
| Montefiore Medical Center | The Bronx, New York, United States | Recruiting |
| Jilin Cancer Hospital | Changchun, Jilin, China | Not Yet Recruiting |
| The first Bethune hospital of Jilin University | Changchun, Jilin, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04412616